537 related articles for article (PubMed ID: 15705997)
1. The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.
Grissom CK; Richer LD; Elstad MR
Chest; 2005 Feb; 127(2):565-70. PubMed ID: 15705997
[TBL] [Abstract][Full Text] [Related]
2. Endothelial selectins in acute mountain sickness and high-altitude pulmonary edema.
Grissom CK; Zimmerman GA; Whatley RE
Chest; 1997 Dec; 112(6):1572-8. PubMed ID: 9404756
[TBL] [Abstract][Full Text] [Related]
3. Leukotriene receptor blockade does not prevent acute mountain sickness induced by normobaric hypoxia.
Luks AM; Henderson WR; Swenson ER
High Alt Med Biol; 2007; 8(2):131-8. PubMed ID: 17584007
[TBL] [Abstract][Full Text] [Related]
4. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
Israel E; Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Shapiro J; Cohn J; Rubin P; Drazen JM
Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1447-51. PubMed ID: 8256883
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization.
Woodruff PG; Albert RK; Bailey WC; Casaburi R; Connett JE; Cooper JA; Criner GJ; Curtis JL; Dransfield MT; Han MK; Harnden SM; Kim V; Marchetti N; Martinez FJ; McEvoy CE; Niewoehner DE; Reilly JJ; Rice K; Scanlon PD; Scharf SM; Sciurba FC; Washko GR; Lazarus SC;
COPD; 2011 Feb; 8(1):21-9. PubMed ID: 21299475
[TBL] [Abstract][Full Text] [Related]
6. Effect of ascent protocol on acute mountain sickness and success at Muztagh Ata, 7546 m.
Bloch KE; Turk AJ; Maggiorini M; Hess T; Merz T; Bosch MM; Barthelmes D; Hefti U; Pichler J; Senn O; Schoch OD
High Alt Med Biol; 2009; 10(1):25-32. PubMed ID: 19326598
[TBL] [Abstract][Full Text] [Related]
7. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
Israel E; Rubin P; Kemp JP; Grossman J; Pierson W; Siegel SC; Tinkelman D; Murray JJ; Busse W; Segal AT; Fish J; Kaiser HB; Ledford D; Wenzel S; Rosenthal R; Cohn J; Lanni C; Pearlman H; Karahalios P; Drazen JM
Ann Intern Med; 1993 Dec; 119(11):1059-66. PubMed ID: 8239223
[TBL] [Abstract][Full Text] [Related]
8. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
Israel E; Cohn J; Dubé L; Drazen JM
JAMA; 1996 Mar; 275(12):931-6. PubMed ID: 8598621
[TBL] [Abstract][Full Text] [Related]
9. Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent.
Gertsch JH; Seto TB; Mor J; Onopa J
High Alt Med Biol; 2002; 3(1):29-37. PubMed ID: 12006162
[TBL] [Abstract][Full Text] [Related]
10. Urinary leukotriene E4 levels increase upon exposure to hypobaric hypoxia.
Roach JM; Muza SR; Rock PB; Lyons TP; Lilly CM; Drazen JM; Cymerman A
Chest; 1996 Oct; 110(4):946-51. PubMed ID: 8874250
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus.
Hackshaw KV; Shi Y; Brandwein SR; Jones K; Westcott JY
J Rheumatol; 1995 Mar; 22(3):462-8. PubMed ID: 7783062
[TBL] [Abstract][Full Text] [Related]
12. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
Liu MC; Dubé LM; Lancaster J
J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):859-71. PubMed ID: 8939149
[TBL] [Abstract][Full Text] [Related]
13. Low-dose theophylline reduces symptoms of acute mountain sickness.
Küpper TE; Strohl KP; Hoefer M; Gieseler U; Netzer CM; Netzer NC
J Travel Med; 2008; 15(5):307-14. PubMed ID: 19006503
[TBL] [Abstract][Full Text] [Related]
14. Remote ischemic preconditioning does not prevent acute mountain sickness after rapid ascent to 3,450 m.
Berger MM; Macholz F; Lehmann L; Dankl D; Hochreiter M; Bacher B; Bärtsch P; Mairbäurl H
J Appl Physiol (1985); 2017 Nov; 123(5):1228-1234. PubMed ID: 28798201
[TBL] [Abstract][Full Text] [Related]
15. Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude.
Bailey DM; Davies B
High Alt Med Biol; 2001; 2(1):21-9. PubMed ID: 11252695
[TBL] [Abstract][Full Text] [Related]
16. Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial.
Baillie JK; Thompson AA; Irving JB; Bates MG; Sutherland AI; Macnee W; Maxwell SR; Webb DJ
QJM; 2009 May; 102(5):341-8. PubMed ID: 19273551
[TBL] [Abstract][Full Text] [Related]
17. Increased Cytokines at High Altitude: Lack of Effect of Ibuprofen on Acute Mountain Sickness, Physiological Variables, or Cytokine Levels.
Lundeberg J; Feiner JR; Schober A; Sall JW; Eilers H; Bickler PE
High Alt Med Biol; 2018 Sep; 19(3):249-258. PubMed ID: 29924642
[TBL] [Abstract][Full Text] [Related]
18. Cysteinyl leukotriene blockade does not prevent acute mountain sickness.
Muza SR; Kaminsky D; Fulco CS; Banderet LE; Cymerman A
Aviat Space Environ Med; 2004 May; 75(5):413-9. PubMed ID: 15152893
[TBL] [Abstract][Full Text] [Related]
19. Training in normobaric hypoxia and its effects on acute mountain sickness after rapid ascent to 4559 m.
Schommer K; Wiesegart N; Menold E; Haas U; Lahr K; Buhl H; Bärtsch P; Dehnert C
High Alt Med Biol; 2010; 11(1):19-25. PubMed ID: 20367484
[TBL] [Abstract][Full Text] [Related]
20. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings.
Kane GC; Pollice M; Kim CJ; Cohn J; Dworski RT; Murray JJ; Sheller JR; Fish JE; Peters SP
J Allergy Clin Immunol; 1996 Feb; 97(2):646-54. PubMed ID: 8621850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
